Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Personalis Inc PSNL

Technology Scientific & Technical Instruments
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome... see more

Recent & Breaking News (NDAQ:PSNL)

Personalis Announces NeXT Level Biomarkers Symposium

Business Wire June 22, 2021

Personalis Announces Delivery of the 125,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program

Business Wire June 2, 2021

Personalis to Participate at the Oppenheimer MedTech, Tools & Diagnostics Summit

Business Wire May 18, 2021

Personalis, Inc. to Present at Biomarkers Week Online 2021

Business Wire May 17, 2021

Personalis Reports First Quarter 2021 Financial Results

Business Wire May 5, 2021

Personalis to Present at the 2021 Bank of America Healthcare Conference

Business Wire April 29, 2021

Personalis to Report First Quarter 2021 Financial Results on May 5, 2021

Business Wire April 21, 2021

Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform®

Business Wire April 8, 2021

Personalis Announces Collaboration with MapKure to Use Personalis' NeXT Platform(TM) for Clinical Trials and Companion Diagnostic Development

Business Wire March 29, 2021

Personalis Announces Changes to its Board of Directors

Business Wire March 8, 2021

Personalis Reports Fourth Quarter and Full Year 2020 Financial Results

Business Wire February 25, 2021

CORRECTING and REPLACING Personalis to Report Fourth Quarter 2020 Financial Results on February 25, 2021

Business Wire February 22, 2021

Natera and Personalis Partner for Personalized Monitoring in Oncology

Business Wire February 17, 2021

Personalis to Present at Upcoming Investor Conferences

Business Wire February 16, 2021

Personalis to Report Fourth Quarter 2020 Financial Results on February 25, 2021

Business Wire February 11, 2021

Personalis Expands Leadership Team with Appointment of Susan Moriconi, VP of People and Chief Human Resources Officer

Business Wire February 8, 2021

Personalis to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Business Wire February 4, 2021

Personalis Announces Pricing of Public Offering of Common Stock

Business Wire January 26, 2021

Personalis Announces Launch of Public Offering of Common Stock

Business Wire January 26, 2021

Personalis Reports Preliminary Fourth Quarter 2020 Revenue

Business Wire January 11, 2021